“Long-Term Efficacy and Safety of Lebrikizumab Is Maintained in Patients With Moderate-to-Severe ​ Atopic Dermatitis: Results Up to 3 Years From ADjoin”. SKIN The Journal of Cutaneous Medicine 9, no. 1 (January 13, 2025): s510. Accessed April 17, 2026. https://skin.dermsquared.com/skin/article/view/3153.